Table 3

 Clinical, haematological, and haemodynamic variables before and after oral bosentan treatment

BasalEnd of observationp Value
dPAP, diastolic pulmonary arterial pressure; Hb, haemoglobin; HR, heart rate; mCWP, mean capillary wedge pressure; mPAP, mean pulmonary arterial pressure ; mSAP, mean systemic arterial pressure; 6MWT, 6-min walk test; NS, not significant; Paco2, systemic arterial CO2; Pao2, systemic arterial O2; pH, systemic arterial pH; Plts, platelets; PVRi, pulmonary vascular resistances index; PVRi/SVRi, pulmonary to systemic vascular resistances ratio; QP, pulmonary cardiac output; QP/QS, pulmonary to systemic cardiac output ratio; QS, systemic cardiac output; RA, right atrial pressure; Sat art O2, transcutaneous oxygen saturation; sPAP, systolic pulmonary arterial pressure; SVRi, systemic vascular resistances index; WCC, white cell count; WHO, World Health Organisation.
Clinical status
Sat art O2 (%)81 (9)87 (6)<0.001
HR (bpm)87 (14)81 (10)<0.05
WHO functional class3.1 (0.7)2.5 (0.7)<0.05
Exercise tolerance: 6MWT
Travelled distance (m)320 (108)394 (73)<0.001
HR at the end (bpm)119 (17)112 (24)NS
Sat art O2 at the end (%)63 (17)71 (14)<0.05
Borg index6.5 (1.3)5.3 (1.8)<0.001
Heart catheterisation pressure
RA (mm Hg)12 (4)11 (3)NS
sPAP (mm Hg)106 (28)105 (37)NS
dPAP (mm Hg)52 (8)49 (16)NS
mPAP (mm Hg)73 (18)71 (22)NS
mCWP (mm Hg)12 (3)12 (4)NS
mSAP (mm Hg)84 (14)83 (18)NS
Blood flow
QP (l/m/m2)2.8 (0.9)4.0 (1.3)<0.001
QS (l/m/m2)3.4 (1.1)4.2 (1.4)<0.05
QP/QS0.9 (0.3)1.0 (0.3)NS
Vascular resistances
PVRi (WU.m2)22 (12)14 (9)<0.001
SVRi (WU.m2)27 (10)23 (11)<0.01
PVRi/SVRi0.9 (0.6)0.6 (0.5)<0.05
Biochemistry
Packed cell volume (%)57 (7)55 (7)NS
Hb (mg/l)180 (40)170 (60)NS
Plts (1000/μl)198 (75)179 (67)NS
WCC (1000/μl)7.4 (2.3)7.2 (2.8)NS
Aspartate aminotranferase (U/l)24 (9)28 (12)NS
Alanine aminotranferase (U/l)31 (21)31 (19)NS
pH7.37 (0.05)7.38 (0.07)NS
Pao2 (mm Hg)45.5 (5.2)50.3 (10.1)NS
Paco2 (mm Hg)39.3 (8.6)38.9 (7.3)NS